scholarly journals GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Mar Achalandabaso Boira ◽  
Marcello Di Martino ◽  
Carlos Gordillo ◽  
Magdalena Adrados ◽  
Elena Martín-Pérez
Keyword(s):  
Glucose Transporter ◽  
Disease Free Survival ◽  
Ductal Adenocarcinoma ◽  
Rank Test ◽  
Free Survival ◽  
Glut 1 ◽  
Kaplan Meier ◽  
Current Therapies ◽  
Worse Prognosis

Abstract Background Various parameters have been considered for predicting survival in pancreatic ductal adenocarcinoma. Information about western population is missing. The aim of this study is to assess the association between Glucose transporter type 1 (GLUT-1) expression and prognosis for patients with PDAC submitted for surgical resection in a European cohort. Methods Retrospective analysis of PDAC specimens after pancreatoduodenectomy assessing GLUT-1 expression according to intensity (weak vs strong) and extension (low if < 80% cells were stained, high if > 80%) was performed. Statistical analysis was performed using the exact Fisher test, Student t test or the Mann-Whitney U test. Survival was analysed using the Kaplan-Meier method and compared with the Log-rank test. The differences were considered significant at a two-sided p value of < 0.05. All statistical analyses were performed using SPSS® 23.0 for Windows (SPSS Inc., Chicago, IL, USA). Results Our study consisted of 39 patients of which 58.9% presented with weak and 41.1% with strong intensity. The median extension was 90%: 28.2% cases presented with a low extension and 71.8% with a high extension. No significant differences related to intensity were found. The high-extension group showed a higher percentage of T3 PDAC (92.9% vs 63.6%, p = 0.042) and LNR20 (35.7% vs 0%, p = 0.037) as well as shorter disease-free survival (17.58 vs 54.46 months; p = 0.048). Conclusions Our findings suggest that GLUT-1 could be related to higher aggressivity in PDAC and could be used as a prognostic marker, identifying patients with a worse response to current therapies who could benefit from more aggressive treatments.

scholarly journals GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival.

2020 ◽  
Author(s):  
Maria del Mar Achalandabaso Boira ◽  
Marcello Di Martino ◽  
Carlos Gordillo ◽  
Magdalena Adrados ◽  
Elena Martín-Pérez
Keyword(s):  
Glucose Transporter ◽  
Disease Free Survival ◽  
Ductal Adenocarcinoma ◽  
Rank Test ◽  
P Value ◽  
Free Survival ◽  
Glut 1 ◽  
Kaplan Meier ◽  
Current Therapies

Abstract Background. Various parameters have been considered for predicting survival in pancreatic ductal adenocarcinoma. Information about western population is missing. The aim of this study is to assess the association between Glucose transporter type 1 (GLUT-1) expression and prognosis for patients with PDAC submitted for surgical resection in a European cohort.Methods. Retrospective analysis of PDAC specimens after pancreatoduodenectomy assessing GLUT-1 expression according to intensity (weak vs strong) and extension (low if <80% cells were stained, high if > 80%) was performed. Statistical analysis was performed using the exact Fisher test, Student t test or the Mann-Whitney U test. Survival was analysed using the Kaplan-Meier method and compared with the Log-rank test. The differences were considered significant at a two-sided p value of < 0.05. All statistical analyses were performed using SPSS® 23.0 for Windows (SPSS Inc., Chicago, IL, USA).Results. Our study consisted of 39 patients of which 58.9% presented with weak and 41.1% with strong intensity. The median extension was 90%: 28.2% cases presented with a low extension and 71.8% with a high extension. No significant differences related to intensity were found. The high-extension group showed a higher percentage of T3 PDAC (92.9% vs 63.6%, p=0.04) and LNR20 (35.7% vs 0%, p=0.03) as well as shorter disease-free survival (17.58 vs 54.46 months; p=0.05).Conclusions. Our findings suggest that GLUT-1 could be related to higher aggressivity in PDAC and could be used as a prognostic marker, identifying patients with a worse response to current therapies who could benefit from more aggressive treatments.

scholarly journals Laparoscopic right posterior sectionectomy versus laparoscopic right hemihepatectomy for hepatocellular carcinoma in posterior segments: Propensity Score Matching Analysis

2018 ◽  
Vol 108 (1) ◽  
pp. 23-29
Author(s):  
J. Rhu ◽  
G. S. Choi ◽  
J. M. Kim ◽  
C. H. D. Kwon ◽  
S. J. Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Disease Free Survival ◽  
Rank Test ◽  
Free Survival ◽  
Right Hemihepatectomy ◽  
Log Rank Test ◽  
Kaplan Meier ◽  
Right Posterior Sectionectomy

Background and Aims: This study was designed to analyze the feasibility of laparoscopic right posterior sectionectomy compared to laparoscopic right hemihepatectomy in patients with hepatocellular carcinoma located in the posterior segments. Material and Methods: The study included patients who underwent either laparoscopic right posterior sectionectomy or laparoscopic right hemihepatectomy for hepatocellular carcinoma located in segment 6 or 7 from January 2009 to December 2016 at Samsung Medical Center. After 1:1 propensity score matching, patient baseline characteristics and operative and postoperative outcomes were compared between the two groups. Disease-free survival and overall survival were compared using Kaplan–Meier log-rank test. Results: Among 61 patients with laparoscopic right posterior sectionectomy and 37 patients with laparoscopic right hemihepatectomy, 30 patients from each group were analyzed after propensity score matching. After matching, baseline characteristics of the two groups were similar including tumor size (3.4 ± 1.2 cm in laparoscopic right posterior sectionectomy vs 3.7 ± 2.1 cm in laparoscopic right hemihepatectomy, P = 0.483); differences were significant before matching (3.1 ± 1.3 cm in laparoscopic right posterior sectionectomy vs 4.3 ± 2.7 cm in laparoscopic right hemihepatectomy, P = 0.035). No significant differences were observed in operative and postoperative data except for free margin size (1.04 ± 0.71 cm in laparoscopic right posterior sectionectomy vs 2.95 ± 1.75 cm in laparoscopic right hemihepatectomy, P < 0.001). Disease-free survival (5-year survival: 38.0% in laparoscopic right posterior sectionectomy vs 47.0% in laparoscopic right hemihepatectomy, P = 0.510) and overall survival (5-year survival: 92.7% in laparoscopic right posterior sectionectomy vs 89.6% in laparoscopic right hemihepatectomy, P = 0.593) did not differ between the groups based on Kaplan–Meier log-rank test. Conclusion: For hepatocellular carcinoma in the posterior segments, laparoscopic right posterior sectionectomy was feasible compared to laparoscopic right hemihepatectomy when performed by experienced laparoscopic surgeons.

Disease-Free Survival for Patients with Thin Melanomas according to the American Joint Committee on Cancer 8th Edition

Dermatology ◽  
2019 ◽  
Vol 235 (4) ◽  
pp. 334-339
Author(s):  
◽  
Luisa Elena Gambra Michel ◽  
Jon Uña Gorospe ◽  
Antonio Luis López Figueroa ◽  
Raquel Mullor Nogales ◽  
...  
Keyword(s):  
Disease Free Survival ◽  
Staging System ◽  
Tnm Staging ◽  
Wilcoxon Test ◽  
Rank Test ◽  
Free Survival ◽  
7Th Edition ◽  
Kaplan Meier ◽  
Disease Free ◽  
8Th Edition

Background: The recently implemented AJCC 8th edition TNM staging system for malignant melanoma (MM) changed the definition for T1a and T1b tumours. Objectives: To analyse differences in disease-free survival (DFS) among patients with thin MM staged according to both AJCC 7th and 8th editions. Methods: An observational study including 285 patients with cutaneous thin MM (thickness ≤1 mm). Cases were staged as T1a and T1b using both 7th and 8th editions. Neither regional nor visceral diseases were present at diagnosis. DFS curves were generated according to the Kaplan-Meier method. Results: An 8% shift of patients from a T1a towards a T1b stage group was observed after applying the AJCC 8th edition. According to this 8th edition, DFS for T1a patients was significantly longer than for T1b patients (log-rank test; p = 0.005); 5-year DFS for T1a and T1b was 100 and 95%, respectively (Wilcoxon test; p = 0.002). According to the AJCC 7th edition, DFS did not significantly differ for T1a and T1b patients; 5-year DFS for T1a and T1b was 99 and 97%, respectively (p > 0.05). Conclusions: The AJCC 8th edition seems to be a better tool for staging thin melanomas.

scholarly journals Evaluasi Terapi  Adjuvant Hormonal  Dan Hubungannya Terhadap Outcome  Klinis  Pasien Kanker Payudara Stadium  Dini Di Kota Padang

2019 ◽  
Vol 5 (3) ◽  
pp. 176
Author(s):  
Wessi Windrasari ◽  
Fatma Sri Wahyuni ◽  
Daan Khambri
Keyword(s):  
Disease Free Survival ◽  
Cross Sectional Study ◽  
Rank Test ◽  
Sectional Study ◽  
Cross Sectional ◽  
Free Survival ◽  
Log Rank Test ◽  
Kaplan Meier ◽  
Her 2 ◽  
Disease Free

Terapi adjuvant hormonal merupakan pilihan terapi yang efektif bagi pasien kanker payudara stadium dini dengan hormonal responsif dan Her-2 negatif. Outcome klinis dari terapi kanker payudara adalah Disease Free Survival (DFS), Overall Survival (OS). Penelitian ini bertujuan mengevaluasi terapi adjuvant hormonal dan pengaruhnya terhadap outcome klinis pasien. Penelitian ini merupakan penelitian deskriptif dengan desain cross sectional study menggunakan data retrospektif registrasi kanker payudara Persatuan Ahli Bedah Onkologi Indonesia (PERABOI) Kota Padang selama periode 2008-2017. Analisis data menggunakan Kaplan Meier Analysis dengan Log rank. Diperoleh sebanyak 58 orang pasien yang memenuhi kriteri inklusi, dengan rerata umur yaitu 49,41 ± 8,69 tahun, kejadian relaps 22,4% dan sebanyak 6,9% pasien mengalami kematian. Terapi terbanyak pada pasien premenopause adalah tamoxifen (58,3%), pada pasien pascamenopause adalah Aromatase Inhibitor (54,5%). Secara statistik pada pasien premenopause tidak ada pengaruh terapi adjuvant hormonal yang berbeda terhadap DFS (P log rank test 0,243 dan HR = 0.513) dan OS (P log rank test 0,545 dan HR = 0.314). Pada pasien pascamenopause tidak ada pengaruh terapi yang berbeda terhadap DFS (P log rank test 0,586 dan HR = 0,10) dan OS (P log rank test 0,594 dan HR = 0,12).

Addition of Taxanes to Platinum and Fluoropyrimidines in Adjuvant Setting Did Not Improve Survival in Patients with Gastric Cancer after Curative Gastrectomy

2020 ◽  
Author(s):  
Lili Wu ◽  
Zhijun Wu ◽  
Hui Xu ◽  
Changhao Wu ◽  
Cheng Zhang ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Gastric Adenocarcinoma ◽  
Disease Free Survival ◽  
Rank Test ◽  
Curative Gastrectomy ◽  
Free Survival ◽  
Log Rank Test ◽  
Kaplan Meier ◽  
Group Survival ◽  
Demonstrate Survival Benefit

Abstract BackgroundTo evaluate whether the addition of taxane to platinum and fluoropyrimidines in adjuvant chemotherapy would result in longer survival than platinum plus fluoropyrimidines in patients who underwent curative gastrectomy.MethodsThis study retrospectively analyzed survival for patients with stage Ⅱ-Ⅲ gastric adenocarcinoma who received curative gastrectomy and adjuvant chemotherapy with platinum plus fluoropyrimidines (PF group) or taxanes and platinum plus fluoropyrimidines (TPF group). Survival curves were estimated using the Kaplan-Meier method, and the differences were compared using the log-rank test.ResultsBaseline characteristics were balanced between the PF group and TPF group. The median disease-free survival (DFS) was 14.9 months (95% CI: 11.0-18.8) in the PF group and 13.8 months (95% CI: 9.3-18.3) in the TPF group (HR=0.90, 95% CI: 0.63-1.29, log-rank test, P=0.560). The median overall survival (OS) was 30.0 months for patients in the PF group (95% CI: 24.5-35.5) and 25.6 months (95% CI: 22.3-28.9) for those in the TPF group (HR=0.93, 95% CI: 0.64-1.35, log-rank test, P=0.705).ConclusionFor stage Ⅱ-Ⅲ gastric adenocarcinoma, the adjuvant triple combination of TPF regimen after curative gastrectomy did not demonstrate survival benefit compared to the PF regimen.

scholarly journals Faktor yang Berpengaruh Terhadap Disease Free Survival dan Overall Survival pada Pasien Kanker Payudara Usia Muda di Kota Padang Tahun 2008 - 2018

2020 ◽  
Vol 9 (1S) ◽  
Author(s):  
Magdi Ayuza ◽  
Wirsma Arif Harahap ◽  
Rony Rustam ◽  
Richvan Dana Nindrea
Keyword(s):  
Overall Survival ◽  
Cohort Study ◽  
Disease Free Survival ◽  
Rank Test ◽  
Free Survival ◽  
Log Rank Test ◽  
Kaplan Meier ◽  
Disease Free ◽  
Data Register

Kanker Payudara (KPD) pada usia muda memiliki keistimewaan karakteristik. Rekurensi KPD dipengaruhi oleh berbagai faktor antara lain faktor klinis, regimen terapi dan biomolekuler dari tumor itu sendiri. Berbagai macam modalitas terapi KPD, namun masih terdapat risiko terjadinya rekurensi terutama pada pasien dewasa muda. Tujuan: Mengetahui faktor-faktor yang mempengaruhi Disease Free Survival (DFS) dan Overall Survival (OS) pada pasien KPD usia muda di Kota Padang. Metode: Penelitian ini menggunakan desain cohort study retrospectif pada pasien KPD usia muda yang telah mendapatkan pengobatan KPD yang memenuhi kriteria inklusi sebanyak 103 sample yang terdapat pada data register KPD PERABOI Padang. Analisis survival menggunakan Kaplan Meier dengan Log Rank Test. Apabila diperoleh nilai p < 0,05, maka terdapat hubungan bermakna. Hasil: Terdapat perbedaan antara setiap faktor klinis, faktor biomolekuler dan faktor terapi dalam hal rata-rata DFS maupun rata-rata OS, namun tidak terdapat pengaruh yang bermakna secara analisis statistik antara faktor terapi (terapi hormon, radioterapi dan terapi target) terhadap DFS dan OS pada pasien kanker payudara usia muda di Kota Padang (p>0,05). Terdapat pengaruh dari pemberian kemoterapi terhadap DFS pada pasien kanker payudara usia muda di Kota Padang (p<0,05). Simpulan: Tidak terdapat hubungan yang bermakna antara faktor klinis dan faktor biomolekuler dengan DFS dan OS, namun terdapat hubungan bermakna antara pemberian kemoterapi dengan DFS dan OS pada penderita KPD usia muda di kota Padang tahun 2008 – 2018.

Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma

2018 ◽  
Vol 25 (5) ◽  
pp. 1432-1439 ◽  
Author(s):  
Hiroshi Kurahara ◽  
Kosei Maemura ◽  
Yuko Mataki ◽  
Masahiko Sakoda ◽  
Satoshi Iino ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Therapeutic Strategy ◽  
Glucose Transporter ◽  
Ductal Adenocarcinoma ◽  
Glut 1

Evaluating associations of diabetes, insulin use, and BMI with efficacy in patients with resected pancreatic cancer: An ancillary analysis of NRG Oncology/RTOG 9704.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 369-369
Author(s):  
Theodore S. Hong ◽  
Kathryn A. Winter ◽  
Charles S. Fuchs ◽  
William Regine ◽  
Ross A. Abrams ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cellular Proliferation ◽  
Disease Free Survival ◽  
Ductal Adenocarcinoma ◽  
Rank Test ◽  
Cox Models ◽  
Kaplan Meier ◽  
Inflammatory State ◽  
Node Involvement ◽  
Insulin Use

369 Background: Diabetes mellitus (DM) has been linked to poor prognosis in pancreatic cancer in numerous retrospective datasets, potentially due to higher levels of insulin and insulin-like growth factor increasing cellular proliferation. Additionally, the hyperglycemic state as well as obesity may lead to a pro-inflammatory state that may enhance tumor progression and metastases. In this analysis, the prognostic significances of diabetes, insulin use, and BMI are evaluated in a prospective, randomized trial of resectable pancreatic ductal adenocarcinoma. Methods: As previously reported, RTOG 9704 pts with resected pancreatic cancer were randomized to 5-fluorouracil (5-FU) or gemcitabine (Gem), given pre and post radiation (RT). Pts in both arms received RT to 50.4 Gy with 5-FU. DM and insulin use were collected on the RTOG 9704 CRFs. BMI was dichotomized as normal/underweight vs. overweight/obese. Overall survival (OS) and disease-free survival (DFS) were estimated by Kaplan-Meier method and variable levels were compared using log-rank test. Cox models were used for multivariable analyses. Results: 538 pts were enrolled from 1998-2002. 238 pts were eligible with analyzable diabetes and insulin use data, in addition to surgical pathology, and CA19-9 data. 32% and 35% of pts in the 5-FU and Gem arms, respectively, had DM. Of which, 24% and 19% used insulin in the 5-FU and Gem arms, respectively. 55% were overweight/obese. The 4 yr OS was 25% (95% CI: 18, 32) in pts with no diabetes, vs. 18% (10, 27) with DM (HR = 1.3 [0.9, 1.7]; p = 0.11). The 4-yr DFS was 14% (9, 20) in pts with no diabetes, vs. 9% (4, 16) with diabetes (HR = 1.2 [0.9, 1.5]; p = 0.31). Neither insulin use nor BMI was univariately associated with OS or DFS. On multivariate analysis, including nodal status, CA19-9, and other variables, DM, insulin use, and BMI were not associated with OS or DFS. Conclusions: DM, insulin use, and BMI were not associated with OS in pts with resected pancreatic cancer treated with adjuvant chemotherapy and chemoradiation. Node involvement and CA19-9 remain the most significant predictors of OS. Supported by NCI grants U10CA180868, U10CA180822, UG1CA189867 and Eli Lilly Clinical trial information: NCT00003216.

Heterogeneity of GNAQ/11 mutation inversely correlates with the metastatic rate in uveal melanoma

2019 ◽  
pp. bjophthalmol-2019-314867
Author(s):  
Chen Liang ◽  
Lan ya Peng ◽  
Ming Zou ◽  
Xuemei Chen ◽  
Yingying Chen ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Disease Free Survival ◽  
Digital Pcr ◽  
Rank Test ◽  
Free Survival ◽  
Log Rank Test ◽  
Metastatic Rate ◽  
Kaplan Meier ◽  
Mutation Ratio ◽  
Disease Free

PurposeTo determine whether the GNAQ/11 mutation correlated with the outcome of patients with uveal melanoma (UM) when genetic heterogeneity was considered.MethodsWe performed a retrospective study of sixty-seven patients with UM. The heterogeneity of GNAQ/11 was examined by using droplet digital PCR. The correlation between metastasis and heterogeneity of the GNAQ/11 mutation was analysed. Disease free survival curves were constructed using the Kaplan-Meier method, and the Wilcoxon log-rank test was used to compare the curves.ResultsThe GNAQ/11 mutation ratio was varied between each case. Among these patients, 28.35% of them harboured homogeneous mutation of GNAQ/11, 62.69% present heterogeneous mutation and 8.96% didn’t present either GNAQ or GNA11 mutation. The tumour with heterogeneous mutation of GNAQ/11 has a higher metastatic rate than that with homogeneous mutation (13/29 vs 1/18, p=0.027). In Kaplan-Meier analysis, metastasis-free survival was not significantly associated with either homogeneous or heterogeneous mutation of GNAQ/11.ConclusionThe mutation ratio of GNAQ/11 in UM was quite variable. The tumour with heterogeneous mutation of GNAQ/11 is more likely to develop a poor prognosis than that with homogeneous mutation of GNAQ/11.

Serial cell-free DNA (cfDNA) sampling in advanced pancreatic ductal adenocarcinoma (PDAC) patients may predict therapeutic outcome.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 423-423
Author(s):  
Gehan Botrus ◽  
Yu Fu ◽  
Mohamad Bassam Sonbol ◽  
Leylah Drusbosky ◽  
Daniel H. Ahn ◽  
...  
Keyword(s):  
Overall Survival ◽  
Progression Free Survival ◽  
Ductal Adenocarcinoma ◽  
Rank Test ◽  
First Line ◽  
Free Survival ◽  
Probability Of Survival ◽  
First Line Therapy ◽  
Kaplan Meier ◽  
Next Generation Sequencing Ngs

423 Background: Advanced PDAC remains a deadly disease with a 5-year survival rate of less than 10%. cfDNA - based next generation sequencing (NGS) may identify actionable alterations in patients with PDAC. In this study, we aim to determine the feasibility of utilizing serial cfDNA NGS testing and its potential relevance in predicting therapeutics outcomes. Methods: A total of 23 PDAC patients with PDAC cfDNA isolated from plasma collected at diagnosis and upon disease progression to first line SOC therapy and were analyzed on a 73-74 gene NGS panel (Guardant Health). Changes in molecular profiles from baseline to progression were analyzed for overall survival, progression free survival (PFS), and treatment response. PFS and OS were analyzed using the Kaplan-Meier method and the log-rank test was used to compare the survival of different groups of patients. All p-values were two-sided. Analyses were performed using R (version 3.5.1, R Foundation, Vienna, Austria). Results: In this retrospective study, the 1-year probability of survival was 71% (median 473 days) and the 1-year PFS was 14% (median 212 days). TP53 and KRAS were the most frequently mutated genes identified in baseline samples, with 78% prevalence for each. Patients with clearance of TP53 17% (3/18) patients and/or KRAS 33% (6/18) patients clones after first line therapy significantly increases PFS (p=0.0056 and p=0.037, with HR of 0.087 and 0.32, respectively). However, appearance of TP53 or KRAS alterations upon progression does not significantly affect overall survival or PFS. Conclusions: The preliminary results from this study suggest that cfDNA clearance of TP53 and/or KRAS alterations may predict for improved PFS in PDAC. Confirmation of these findings in larger studies is warranted.

Sign in / Sign up

Export Citation Format

Share Document